ANI Pharmaceuticals
ANIP
200 hedge funds and large institutions have $975M invested in ANI Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 64 increasing their positions, 54 reducing their positions, and 22 closing their positions.
86% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 22
28% more capital invested
Capital invested by funds: $764M → $975M (+$212M)
19% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 54
10% more funds holding
Funds holding: 182 → 200 (+18)
0.81% less ownership
Funds ownership: 67.78% → 66.98% (-0.81%)
91% less call options, than puts
Call options by funds: $3.41M | Put options by funds: $39.2M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$13.4M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.06M |
| 3 |
SCM
Sio Capital Management
New York
|
+$5.27M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$5.24M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$3.96M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$12.8M |
| 2 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
-$11.6M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$10M |
| 4 |
SC
Stempoint Capital
New York
|
-$4.71M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.33M |
ANIP Hedge Fund Activity: Q1 2024 in Review
200 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2024, worth a combined $975M — up 28% from $764M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ANIP positions and 22 closed out — a net gain of 19 holders — while 64 added to existing stakes and 54 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $13.4M. The largest seller was Morgan Stanley, cutting an estimated $12.8M.
- 200 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2024, up from 182 in Q4 2023.
- Funds reported $975M of ANI Pharmaceuticals stock for Q1 2024, up 28% quarter-over-quarter.
- 41 funds opened new ANI Pharmaceuticals positions in Q1 2024 and 22 closed out, a net change of +19 holders.
- The largest ANI Pharmaceuticals buyer in Q1 2024 was Deep Track Capital, an estimated $13.4M added.
- The largest ANI Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $12.8M sold.
Based on aggregated 13F filings for Q1 2024.